Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

(2009) M. Jadzinsky et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

(2009) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

(2009) K. B. Hansen et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

(2009) A. R. Chacra et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

(2008) Jay S. Skyler et al.   CIRCULATION

Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial--Revisited

(2008) J. M. Lachin et al.   DIABETES

Glycemic Variability: Should we and can we prevent it?

(2008) L. Monnier et al.   DIABETES CARE

Economic Costs of Diabetes in the U.S. in 2007

(2008)   DIABETES CARE

Translating the A1C Assay Into Estimated Average Glucose Values

(2008) D. M. Nathan et al.   DIABETES CARE

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

(2008) S. E. Kahn et al.   DIABETES CARE

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Glycemic Targets and Cardiovascular Disease

(2008) William T. Cefalu   NEW ENGLAND JOURNAL OF MEDICINE

Intensive Glycemic Control in the ACCORD and ADVANCE Trials

(2008) Robert G. Dluhy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

(2008) Debora Williams-Herman et al.   BMC Endocrine Disorders